Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality Assurance of HER2/neu Testing by Immunohistochemistry and Fluorescence In Situ Hybridization

Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality... TECHNICAL REPORT Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality Assurance of HER2/neu Testing by Immunohistochemistry and Fluorescence In Situ Hybridization Lester J. Layfield, MD,* Carlynn Willmore-Payne, BS, MT (ASCP),w Gary Isom, BS, MT (ASCP),w and Joseph A. Holden, MD, PhD* Key Words: HER2, FISH, immunohistochemistry, quality Background: Assessment of HER2 by immunohistochemistry assurance (IHC) or fluorescence in situ hybridization (FISH) is a standard (Appl Immunohistochem Mol Morphol 2008;16:562–567) practice for breast carcinomas. Testing is associated with a 20% disagreement between laboratories. The College of American Pathologists (CAP) guidelines for HER2 testing include valida- tion of HER2 test methods by achieving 95% concordance with ssessment of HER2 is routinely performed in newly another validated method. Our laboratory requires IHC 3+ Adiagnosed invasive carcinomas of the breast. FISH nonamplified specimens to undergo retesting by poly- Although several methods exist for HER2 assessment, merase chain reaction (PCR). A random sample of IHC 2+ the optimal method has not yet been identified. Im- cases are routinely tested by PCR. We found this practice useful munohistochemistry (IHC) and fluorescence in situ for resolving discrepancies in HER2 testing. hybridization (FISH) represent the two most widely used technologies currently available. HER2 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality Assurance of HER2/neu Testing by Immunohistochemistry and Fluorescence In Situ Hybridization

Loading next page...
 
/lp/wolters-kluwer-health/monoplex-lightcycler-polymerase-chain-reaction-quantitation-of-the-Ll1JpN00Ul
ISSN
1541-2016
DOI
10.1097/PAI.0b013e318171923a
pmid
18948825
Publisher site
See Article on Publisher Site

Abstract

TECHNICAL REPORT Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality Assurance of HER2/neu Testing by Immunohistochemistry and Fluorescence In Situ Hybridization Lester J. Layfield, MD,* Carlynn Willmore-Payne, BS, MT (ASCP),w Gary Isom, BS, MT (ASCP),w and Joseph A. Holden, MD, PhD* Key Words: HER2, FISH, immunohistochemistry, quality Background: Assessment of HER2 by immunohistochemistry assurance (IHC) or fluorescence in situ hybridization (FISH) is a standard (Appl Immunohistochem Mol Morphol 2008;16:562–567) practice for breast carcinomas. Testing is associated with a 20% disagreement between laboratories. The College of American Pathologists (CAP) guidelines for HER2 testing include valida- tion of HER2 test methods by achieving 95% concordance with ssessment of HER2 is routinely performed in newly another validated method. Our laboratory requires IHC 3+ Adiagnosed invasive carcinomas of the breast. FISH nonamplified specimens to undergo retesting by poly- Although several methods exist for HER2 assessment, merase chain reaction (PCR). A random sample of IHC 2+ the optimal method has not yet been identified. Im- cases are routinely tested by PCR. We found this practice useful munohistochemistry (IHC) and fluorescence in situ for resolving discrepancies in HER2 testing. hybridization (FISH) represent the two most widely used technologies currently available. HER2

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Dec 1, 2008

There are no references for this article.